ライフサイエンスコーパス: antibody-dependent

1 GLP-1R) expression in alpha-cells using both antibody-dependent and antibody-independent strategies.

2 This immunity was antibody dependent, as evidenced by the complete loss of

3 ly susceptibility of its antigen variants to antibody-dependent bactericidal killing.

4 ulate the rate of target cell destruction in antibody-dependent cell cytotoxicity (ADCC).

5 IPH4102 antitumor activity was mediated by antibody-dependent cell cytotoxicity and phagocytosis.

6 activity, anti-CMV IgG, and NK cell-mediated antibody-dependent cell cytotoxicity were present in ale

7 expression and degranulation, and natural or antibody-dependent cell cytotoxicity, in comparison with

8 For example, in antibody-dependent cell cytotoxicity-a major mode of act

9 tential role of natural killer cell-mediated antibody-dependent cell cytotoxicity.

10 as prominent effector cells and induction of antibody-dependent cell phagocytosis as one of the prima

11 the immunologic synapse and potently induce antibody-dependent cell-mediated antiviral responses: (i

12 Antibody-dependent cell-mediated cytotoxic activity agai

13 d with their parental forms, potent in vitro antibody-dependent cell-mediated cytotoxicity (0.1-0.3 m

14 ental insights into the relationship between antibody-dependent cell-mediated cytotoxicity (ADCC) and

15 histochemistry, for affinity by BIACORE, for antibody-dependent cell-mediated cytotoxicity (ADCC) and

16 Moreover, antibody-dependent cell-mediated cytotoxicity (ADCC) ass

17 Results from serum transfer experiments and antibody-dependent cell-mediated cytotoxicity (ADCC) ass

18 to ipilimumab by multicolor flow cytometry, antibody-dependent cell-mediated cytotoxicity (ADCC) ass

19 Antibody-dependent cell-mediated cytotoxicity (ADCC) by

20 es that enhance tumor cell susceptibility to antibody-dependent cell-mediated cytotoxicity (ADCC) by

21 but their potential for cancer treatment via antibody-dependent cell-mediated cytotoxicity (ADCC) has

22 Antibody-dependent cell-mediated cytotoxicity (ADCC) is

23 Antibody-dependent cell-mediated cytotoxicity (ADCC) is

24 te Fc gama receptors (FcgammaRs) and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) may

25 ogenic species of Ebola viruses and elicited antibody-dependent cell-mediated cytotoxicity (ADCC) res

26 the susceptibility of HIV-infected cells to antibody-dependent cell-mediated cytotoxicity (ADCC), an

27 n, endowed with increased ability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC), du

28 effector functions of antibodies, including antibody-dependent cell-mediated cytotoxicity (ADCC), in

29 asure the killing of virus-infected cells by antibody-dependent cell-mediated cytotoxicity (ADCC), we

30 iller (NK) cells to kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC).

31 enhanced virus replication and resistance to antibody-dependent cell-mediated cytotoxicity (ADCC).

32 ic antibodies, arising in part from enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).

33 ured by glycans that either promote or block antibody-dependent cell-mediated cytotoxicity (ADCC).

34 ability to eliminate virus-infected cells by antibody-dependent cell-mediated cytotoxicity (ADCC).

35 unctions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC).

36 their surface are preferentially targeted by antibody-dependent cell-mediated cytotoxicity (ADCC).

37 eutralization, binding to infected cells, or antibody-dependent cell-mediated cytotoxicity (ADCC).

38 Substantial effector functional activities (antibody-dependent cell-mediated cytotoxicity and antibo

39 (hYP7 and hYP9.1b) in the IgG format induced antibody-dependent cell-mediated cytotoxicity and comple

40 The lack of effector functions, such as antibody-dependent cell-mediated cytotoxicity and comple

41 anti-neuraminidase antibodies weakly induced antibody-dependent cell-mediated cytotoxicity and enhanc

42 binding, neuraminidase inhibition, in vitro antibody-dependent cell-mediated cytotoxicity and in viv

43 Antibody-dependent cell-mediated cytotoxicity and tier 1

44 Despite this, reverse antibody-dependent cell-mediated cytotoxicity assays sho

45 feron gamma production, resulting in greater antibody-dependent cell-mediated cytotoxicity compared w

46 In addition, SEFL variants demonstrated no antibody-dependent cell-mediated cytotoxicity in vitro a

47 odies displayed cellular phagocytosis and/or antibody-dependent cell-mediated cytotoxicity in vitro O

48 outbreak variants of Ebola virus and mediate antibody-dependent cell-mediated cytotoxicity in vitro.

49 ying specificities regulate the magnitude of antibody-dependent cell-mediated cytotoxicity induction.

50 ing antibodies, neutralising antibodies, and antibody-dependent cell-mediated cytotoxicity measured 2

51 eptor affinity maturation and defects in the antibody-dependent cell-mediated cytotoxicity pathway.

52 Activity in an antibody-dependent cell-mediated cytotoxicity reporter a

53 ations in the MICA and MICB genes related to antibody-dependent cell-mediated cytotoxicity were ident

54 chanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antib

55 TF:FVIIa-dependent intracellular signaling, antibody-dependent cell-mediated cytotoxicity, and rapid

56 e activation of natural killer (NK) cells by antibody-dependent cell-mediated cytotoxicity, both RIFI

57 d optimized structure for the enhancement of antibody-dependent cell-mediated cytotoxicity, complemen

58 receptor alpha that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patie

59 ween milk or plasma neutralization activity, antibody-dependent cell-mediated cytotoxicity, or HIV-1

60 ticular the IgG1 and IgG3 subclass mediating antibody-dependent cell-mediated cytotoxicity, seem to p

61 and engagement of myeloid effector cells for antibody-dependent cell-mediated cytotoxicity, were simi

62 N9) vaccines elicited robust, cross-reactive antibody-dependent cell-mediated cytotoxicity-mediating

63 On NK cells, 4-1BB signaling can increase antibody-dependent cell-mediated cytotoxicity.

64 N9 virus through mechanisms likely involving antibody-dependent cell-mediated cytotoxicity.

65 odies were poor inducers and did not inhibit antibody-dependent cell-mediated cytotoxicity.

66 Antibody-dependent cell-mediated phagocytosis (ADCP) was

67 ent cellular cytotoxicity (ADCC), and modest antibody-dependent cell-mediated virus inhibition (ADCVI

68 ody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated virus inhibition) were

69 l blood mononuclear cell assay, and moderate antibody-dependent, cell-mediated cytotoxicity activity

70 and fixation as well as Fc-gamma-dependent, antibody-dependent, cell-mediated cytotoxity in both mur

71 An antibody dependent cellular phagocytosis (ADCP) assay re

72 ecificity) and effector function activities (antibody dependent cellular phagocytosis, cellular cytot

73 the five neutralizing MAbs exhibited strong antibody-dependent cellular cytotoxicity (ADCC) activity

74 (Abs) to the V1V2 region of gp120 with high antibody-dependent cellular cytotoxicity (ADCC) activity

75 and that this protection may correlate with antibody-dependent cellular cytotoxicity (ADCC) activity

76 lobulin G1 antibody variant with compromised antibody-dependent cellular cytotoxicity (ADCC) activity

77 ust cross-clade binding and neutralizing and antibody-dependent cellular cytotoxicity (ADCC) activity

78 is V3 specificity correlated with measurable antibody-dependent cellular cytotoxicity (ADCC) activity

79 ngly, the presence of antibodies with potent antibody-dependent cellular cytotoxicity (ADCC) activity

80 bodies) show reduced FcgammaR engagement and antibody-dependent cellular cytotoxicity (ADCC) activity

81 n both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) activity

82 Antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against

83 ility to opsonize viral particles, to direct antibody-dependent cellular cytotoxicity (ADCC) against

84 b) directs natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against

85 The ALVAC/AIDSVax vaccine induced antibody-dependent cellular cytotoxicity (ADCC) against

86 iminating latent HIV infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and anti

87 d recycling, Fc effector activities, such as antibody-dependent cellular cytotoxicity (ADCC) and phag

88 These Treg suppressed cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and thei

89 HIV-1-specific antibody-dependent cellular cytotoxicity (ADCC) antibodi

90 s immunized by only the i.m. route had lower antibody-dependent cellular cytotoxicity (ADCC) antibody

91 s by competition with ACE2 but could involve antibody-dependent cellular cytotoxicity (ADCC) as IgG1

92 An antibody-dependent cellular cytotoxicity (ADCC) assay wa

93 Natural killer (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by aggre

94 ycan fucosylation have been shown to improve antibody-dependent cellular cytotoxicity (ADCC) by allow

95 ible (CDi) neutralizing epitopes targeted by antibody-dependent cellular cytotoxicity (ADCC) effector

96 oss-reactive antibodies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) effector

97 onses at an early time point correlated with antibody-dependent cellular cytotoxicity (ADCC) function

98 virus type 1 (HIV-1) Env and able to mediate antibody-dependent cellular cytotoxicity (ADCC) have bee

99 ng evidence supports a role for HIV-specific antibody-dependent cellular cytotoxicity (ADCC) in contr

100 we examined type-specific and cross-reactive antibody-dependent cellular cytotoxicity (ADCC) in HIV-1

101 to increase FcgammaRIII binding and improve antibody-dependent cellular cytotoxicity (ADCC) in vitro

102 Antibody-dependent cellular cytotoxicity (ADCC) is a key

103 Antibody-dependent cellular cytotoxicity (ADCC) is media

104 Antibody-dependent cellular cytotoxicity (ADCC) may be a

105 Therefore, antibody-dependent cellular cytotoxicity (ADCC) may play

106 Nonneutralizing antibodies (Abs) involved in antibody-dependent cellular cytotoxicity (ADCC) may prov

107 Treg depletion was mediated through the antibody-dependent cellular cytotoxicity (ADCC) mechanis

108 but not natural killer (NK) cells to induce antibody-dependent cellular cytotoxicity (ADCC) of alpha

109 Elimination of HIV-1-infected cells by antibody-dependent cellular cytotoxicity (ADCC) requires

110 levels of HIV-1-neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) response

111 itopes) as targets of potentially protective antibody-dependent cellular cytotoxicity (ADCC) response

112 The correlation of HIV-specific antibody-dependent cellular cytotoxicity (ADCC) response

113 cellular phagocytosis of HIV-1 virions, and antibody-dependent cellular cytotoxicity (ADCC) response

114 There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to elimi

115 e HIV-1 reservoir.IMPORTANCE Mobilization of antibody-dependent cellular cytotoxicity (ADCC) to elimi

116 protein expressed by infected cells mobilize antibody-dependent cellular cytotoxicity (ADCC) to elimi

117 Antibody-dependent cellular cytotoxicity (ADCC) was meas

118 ating the factors that modulate HIV-specific antibody-dependent cellular cytotoxicity (ADCC) will hel

119 d more stem-specific antibodies, with higher antibody-dependent cellular cytotoxicity (ADCC), and bet

120 e breadth of HIV-1 gp120 and V1V2 responses, antibody-dependent cellular cytotoxicity (ADCC), and low

121 The MAbs mediated antibody-dependent cellular cytotoxicity (ADCC), and mic

122 Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and mod

123 functions, including tier 1 neutralization, antibody-dependent cellular cytotoxicity (ADCC), infecte

124 antibodies (MAbs) frequently mediate potent antibody-dependent cellular cytotoxicity (ADCC), making

125 cts on virus infectivity, antibodies mediate antibody-dependent cellular cytotoxicity (ADCC), the kil

126 ese epitopes and sensitize infected cells to antibody-dependent cellular cytotoxicity (ADCC), we trea

127 e, core fucosylation significantly decreases antibody-dependent cellular cytotoxicity (ADCC), whereas

128 One such mechanism is antibody-dependent cellular cytotoxicity (ADCC), whereby

129 ase of cell reinfection, and protection from antibody-dependent cellular cytotoxicity (ADCC), which i

130 Cross-reactive influenza virus-specific antibody-dependent cellular cytotoxicity (ADCC)-activati

131 ed that human natural killer (NK) cells, via antibody-dependent cellular cytotoxicity (ADCC)-like mec

132 elope glycoproteins is the primary target of antibody-dependent cellular cytotoxicity (ADCC)-mediatin

133 tion with either lineage induces HA-specific antibody-dependent cellular cytotoxicity (ADCC)-mediatin

134 ural killer (NK) cells resulting in crippled antibody-dependent cellular cytotoxicity (ADCC).

135 diminished natural cytotoxicity but enhanced antibody-dependent cellular cytotoxicity (ADCC).

136 uces the susceptibility of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

137 v conformation and affects the efficiency of antibody-dependent cellular cytotoxicity (ADCC).

138 es, possibly owing to its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).

139 ncreases susceptibility of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

140 (NK)-cell degranulation and NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

141 d rafts and is glycoengineered for augmented antibody-dependent cellular cytotoxicity (ADCC).

142 dividuals contain antibodies able to mediate antibody-dependent cellular cytotoxicity (ADCC).

143 inate cells reactivated from latency through antibody-dependent cellular cytotoxicity (ADCC).

144 marily by activating Fc receptors to mediate antibody-dependent cellular cytotoxicity (ADCC).

145 lso kills MET-overexpressing cancer cells by antibody-dependent cellular cytotoxicity (ADCC).

146 ve demonstrated that CD4i antibodies mediate antibody-dependent cellular cytotoxicity (ADCC).

147 d NK cell degranulation and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

148 Env in this conformation are susceptible to antibody-dependent cellular cytotoxicity (ADCC).

149 s the target for neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC).

150 Env to nnAbs and sensitize infected cells to antibody-dependent cellular cytotoxicity (ADCC).

151 sponses (characterized by increased in vitro antibody-dependent cellular cytotoxicity [ADCC] activity

152 infected cells by natural killer (NK) cells (antibody-dependent cellular cytotoxicity [ADCC]) or comp

153 g to FcgammaRIIIA and thereby decreasing the antibody-dependent cellular cytotoxicity activities.

154 er, we found no difference in serum in vitro antibody-dependent cellular cytotoxicity activity.

155 An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+H

156 fic CD16(pos) gammadelta T cells can perform antibody-dependent cellular cytotoxicity against stromal

157 ti-IL1RAP antibody capable of both achieving antibody-dependent cellular cytotoxicity and blocking of

158 pecific monoclonal antibodies display robust antibody-dependent cellular cytotoxicity and CD4-depende

159 The antibody-dependent cellular cytotoxicity and complement-

160 tes killing of infected cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-

161 oinflammatory direct cell killing to promote antibody-dependent cellular cytotoxicity and complement-

162 f a CD20-targeting antibody had no impact on antibody-dependent cellular cytotoxicity and did not cha

163 In contrast, antibody-dependent cellular cytotoxicity and T cell acti

164 odification in the Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically r

165 ivation of the classical complement pathway, antibody-dependent cellular cytotoxicity by innate immun

166 he asymmetrically engineered Fc variants for antibody-dependent cellular cytotoxicity enhancement cou

167 Our study highlights the potential role that antibody-dependent cellular cytotoxicity might play in a

168 mulation, by the use of antibodies to induce antibody-dependent cellular cytotoxicity or to block iKI

169 an HIV-1 Env vaccine increased C1C2-specific antibody-dependent cellular cytotoxicity potency and bre

170 NSCC sensitivity in a manner associated with antibody-dependent cellular cytotoxicity rather than EGF

171 levels of IgA antibodies, and high levels of antibody-dependent cellular cytotoxicity responses and H

172 Adaptive NK cells dominated antibody-dependent cellular cytotoxicity responses, and

173 In each study, protection correlated with antibody-dependent cellular cytotoxicity specific for CD

174 They can mediate antibody-dependent cellular cytotoxicity to eradicate tu

175 r not only induced gp140-specific IgG, ADCC (antibody-dependent cellular cytotoxicity) and some neutr

176 ed in N. benthamiana are capable of inducing antibody-dependent cellular cytotoxicity, an activity no

177 including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-depen

178 ts from a panel of exploratory immunoassays (antibody-dependent cellular cytotoxicity, CD4+ T-cell cy

179 Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to

180 2M activates natural killer cells to enhance antibody-dependent cellular cytotoxicity, mediates compl

181 d functional activity (virus neutralization, antibody-dependent cellular cytotoxicity, phagocytosis,

182 f natural killer cells, the key mediators of antibody-dependent cellular cytotoxicity, to human AMR i

183 IgG are potent effectors of complement- and antibody-dependent cellular cytotoxicity, which are crit

184 biting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests

185 ) arm that was derived from broadly binding, antibody-dependent cellular cytotoxicity-mediating antib

186 elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity.

187 ces from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity.

188 ces from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity.

189 -induced (CD4i) antibodies capable of potent antibody-dependent cellular cytotoxicity.

190 enhancing NK cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.

191 ediated by donor-specific antibodies through antibody-dependent cellular cytotoxicity.

192 lectivity, as well as, interestingly, higher antibody-dependent cellular cytotoxicity.

193 bs, readily induced by vaccines, can trigger antibody-dependent cellular effector functions, through

194 es and to inhibit parasite growth through an antibody-dependent cellular inhibition mechanism.

195 ed functional activities, including ADCC and antibody-dependent cellular phagocytosis (ADCP) activiti

196 Their studies revealed that antibody-dependent cellular phagocytosis (ADCP) and Fcga

197 ve antitumor antibody responses by enhancing antibody-dependent cellular phagocytosis (ADCP) in xenog

198 ecruitment of Fcgamma receptors (FcgammaRs), antibody-dependent cellular phagocytosis (ADCP), and the

199 xenografts by enhancing macrophage-mediated antibody-dependent cellular phagocytosis (ADCP), but syn

200 However, there was little change in the antibody-dependent cellular phagocytosis activity.

201 h a SIRPalpha-CD45 RIPR molecule potentiates antibody-dependent cellular phagocytosis beyond that of

202 wo FCGR2B SNPs influenced whether anti-gp140 antibody-dependent cellular phagocytosis correlated sign

203 ody levels and immunodominant specificities, antibody-dependent cellular phagocytosis of HIV-1 virion

204 6M0-mcMMAF recruits macrophages and mediates antibody-dependent cellular phagocytosis of MM cells.

205 dy-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apo

206 ores, neutralizing antibody (nAb) responses, antibody-dependent cellular phagocytosis, CD4+ polyfunct

207 Antibody-dependent cellular phagocytosis, Env-specific I

208 y, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, programmed cel

209 to avidly capture HIV virions and to mediate antibody-dependent cellular phagocytosis, suggesting a r

210 vo, namely antibody-induced inflammation and antibody-dependent cellular phagocytosis.

211 D16, the Fc receptor (FcgammaIII) to mediate antibody-dependent cellular toxicity (ADCC), for a precl

212 their surface are preferentially targeted by antibody-dependent cellular-mediated cytotoxicity (ADCC)

213 I antibodies of various isotypes in ADCC and antibody-dependent cellular-phagocytosis (ADCP) assays.

214 ere form of rejection, mediated primarily by antibody-dependent complement (C) activation.

215 ng capacity) and has increased resistance to antibody-dependent complement-mediated killing compared

216 ndings indicate that increased resistance to antibody-dependent complement-mediated killing secondary

217 ors of complement activation (RCA) to resist antibody-dependent complement-mediated lysis (ADCML).

218 Antibody-dependent cytotoxicity became detectable 3 mont

219 ation activity limited to tier 1 viruses and antibody-dependent cytotoxicity responses (ADCC) after D

220 tion of TEMRA CD8(+) T cells, which mediated antibody-dependent cytotoxicity.

221 cells with tumor cells, which can result in antibody-dependent cytotoxicity.

222 envelope and neutralize the virus or mediate antibody-dependent cytotoxicity.

223 ding, neutralized H5N1 viruses, and mediated antibody-dependent effector activity.

224 v antigen engagement which lead to effective antibody-dependent effector function directed to the non

225 s provide additional evidence that effective antibody-dependent effector function in the cluster A re

226 Might COVID-19 vaccines sensitize humans to antibody-dependent enhanced (ADE) breakthrough infection

227 Neutralization and antibody-dependent enhanced replication experiments show

228 ion showed significant capacity for in vitro antibody dependent enhancement of Dengue-1, 2, 3 and 4 s

229 Crosslinking of Fc with FcgammaRIIB mediates antibody-dependent enhancement (ADE) activity by MW05.

230 evere dengue disease focus on the process of antibody-dependent enhancement (ADE) as a primary risk f

231 Antibody-dependent enhancement (ADE) is a mechanism by w

232 The proposed antibody-dependent enhancement (ADE) mechanism for sever

233 tate Zika virus (ZIKV) infection through the antibody-dependent enhancement (ADE) mechanism.

234 uses, which may aggravate the disease via an antibody-dependent enhancement (ADE) mechanism.

235 Th1-biased response in mice, and there is no antibody-dependent enhancement (ADE) observed.

236 Antibody-dependent enhancement (ADE) of dengue virus (DE

237 protection against DENV disease and prevents antibody-dependent enhancement (ADE) of disease in mice.

238 Antibody-dependent enhancement (ADE) of disease is a gen

239 rns for cross-reactive responses that induce antibody-dependent enhancement (ADE) of heterologous fla

240 oorly neutralizing antibodies that can cause antibody-dependent enhancement (ADE) of infection.

241 cination and antiviral strategies.IMPORTANCE Antibody-dependent enhancement (ADE) of viral entry has

242 Antibody-dependent enhancement (ADE) of viral entry has

243 mmune serum, it has been shown in vitro that antibody-dependent enhancement (ADE) of ZIKV infection c

244 ble of both cross-neutralization, as well as antibody-dependent enhancement (ADE) of ZIKV infection.

245 cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection.

246 Moreover, antibody-dependent enhancement (ADE) was not observed ag

247 infection of myeloid cells-a process termed antibody-dependent enhancement (ADE)(1,4,5).

248 e virus (DENV) infections is associated with antibody-dependent enhancement (ADE), and it was recentl

249 This phenomenon is referred to as antibody-dependent enhancement (ADE).

250 tope antibodies that are known to facilitate antibody-dependent enhancement (ADE).

251 eutralization potency, enhanced infection by antibody-dependent enhancement (ADE).

252 SARS-CoV-2, including somatic mutations and antibody-dependent enhancement (ADE).

253 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE).

254 Progression to DHF/DSS is attributed to antibody-dependent enhancement (ADE); however, because o

255 tions in flavivirus immune vaccinees such as Antibody-Dependent Enhancement (ADE, a phenomenon involv

256 ovide statistical support for the process of antibody-dependent enhancement (but not original antigen

257 DENV infection was enhanced (through antibody-dependent enhancement [ADE]) or was suppressed

258 ve broad HA reactivity, yet they do not have antibody-dependent enhancement activity.

259 ines identified cellular immunopathology and antibody-dependent enhancement as potential safety issue

260 Antibody-dependent enhancement has been implicated in mo

261 For decades antibody-dependent enhancement has been the prevalent mo

262 , and provides evidence for the mechanism of antibody-dependent enhancement in dengue cases.

263 ZIKV co-circulate, understanding the role of antibody-dependent enhancement in the context of pregnan

264 Among the 4 serotypes of dengue virus, antibody-dependent enhancement is thought to enhance vir

265 Antibody-dependent enhancement may explain the severe di

266 While antibody-dependent enhancement of dengue is thought to b

267 I agonist blocked both primary infection and antibody-dependent enhancement of DENV infection.

268 mune effector functions but could potentiate antibody-dependent enhancement of disease.

269 , indicating their possible ability to cause antibody-dependent enhancement of disease.

270 ucleoside-modified mRNA vaccines do not show antibody-dependent enhancement of infection in vitro.

271 mRNA vaccines, including one that minimizes antibody-dependent enhancement of infection, elicited hi

272 Although suspected, such antibody-dependent enhancement of severe disease has not

273 nd vice versa because of a phenomenon termed antibody-dependent enhancement.

274 igenetic modification of gene expression and antibody-dependent expansion.

275 mma-deficient NK cells that display enhanced antibody-dependent functional activity.

276 st closely paralleled clinical outcomes, IgE antibody-dependent functional assays remained inhibited

277 lactose epitope bound by IgM that results in antibody-dependent killing via the classical pathway of

278 ly induced lymphoma Gal-1 expression ablated antibody-dependent lymphoma phagocytosis in vitro and ly

279 Thus, antibody-dependent lysis of P. falciparum-infected RBCs

280 tor IV expression on macrophages, leading to antibody-dependent macrophage-mediated depletion of regu

281 hils (PPNs) killed chlamydiae in vitro in an antibody-dependent manner.

282 fected cells (both HCMV and influenza) in an antibody-dependent manner.

283 Antibody-dependent mast cell activation constitutes a no

284 ovide epidemiological evidence that multiple antibody-dependent mechanisms contribute to protective i

285 rasites more precisely, particularly through antibody-dependent mechanisms.

286 n a prespecified immune correlates analysis, antibody-dependent monocyte phagocytosis and antibody bi

287 SEFL mutations eliminated off-target antibody-dependent monocyte phagocytosis of cynomolgus m

288 of FcgammaR function dramatically inhibited antibody-dependent murine ITP and successfully circumven

289 Antibody-dependent neutralization of secreted DDT exacer

290 ted functional antibody responses, including antibody-dependent neutrophil/monocyte phagocytosis, com

291 pact of NK cell differentiation phenotype on antibody-dependent NK cell activation, with highly diffe

292 Enhanced levels of CD16 expression and antibody-dependent NK cell cytotoxic function of HT reci

293 Consideration of antibody-dependent NK cell responses to P. falciparum an

294 to the production of class-switched anti-MOG antibodies, dependent on the presence of hemagglutinin-s

295 ed binding antibody against scaffolded V1V2, antibody-dependent phagocytic activity against VLP-coate

296 y-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), are unclear.

297 As an example, we demonstrate that antibody-dependent phagocytosis is more efficient for ta

298 PPD-specific isotype/subclass, PPD-specific antibody-dependent phagocytosis, cellular cytotoxicity,

299 Here we optimize the antibody-dependent respiratory burst (ADRB) assay, which

300 Moreover, the effect of SERINC5 on antibody-dependent virus capture was abrogated by Nef ex